TRCT
EPRX

Tower Research Capital (TRC)’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Tower Research Capital (TRC)’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9
Closed -$53 – 5694
2025
Q3 		$53 Buy
+9
New +$49 ﹤0.01% 5143

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Tower Research Capital (TRC)'s EPRX Position: Q4 2025 in Review

Tower Research Capital (TRC) sold out of Eupraxia Pharmaceuticals (EPRX) in Q4 2025, closing a stake of 9 shares — an estimated $53 sold.

Tower Research Capital (TRC) first reported a position in EPRX in Q3 2025 and held it in 1 quarter. The position peaked at $53 in Q3 2025. 35 funds tracked by Wall St. Rank hold EPRX as of Q4 2025.

  • Tower Research Capital (TRC) reported no remaining Eupraxia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 9 Eupraxia Pharmaceuticals shares in Q4 2025, an estimated $53.
  • Tower Research Capital (TRC) first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Tower Research Capital (TRC)'s Eupraxia Pharmaceuticals position peaked at $53 in Q3 2025.
  • 35 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q4 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.